CVRX - CVRx Announces Appointment of Kevin Hykes as President and Chief Executive Officer | Benzinga
- Appointment effective February 12 following Nadim Yared's retirement
- Hykes currently serves as Augmedics' President and CEO, and has served on CVRx's Board of Directors since 2022
MINNEAPOLIS, Jan. 31, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company, announced today the appointment of Kevin Hykes as the Company's new President and Chief Executive Officer, effective February 12. Hykes will continue to serve on the Company's Board of Directors. Yared will retire from the Company and resign his Board seat concurrent with Hykes' appointment and has agreed to consult with the Company to ensure a seamless transition.
Hykes is an accomplished medical device industry executive with 30 years' experience commercializing novel therapies around the globe and has a deep understanding of CVRx, having served on the Company's Board of Directors since December 2022. He has served as President and CEO for several early to mid-stage, high-growth companies, including in the neuromodulation and cardiovascular fields. Hykes currently serves as the President and CEO of Augmedics, a pioneer in augmented reality surgical navigation. Prior to joining Augmedics, he was President and CEO of Bardy Diagnostics, which was acquired by Hillrom in August 2021. Before Bardy Diagnostics, Hykes was President and CEO of Relievant Medsystems, an Operating Partner at Versant Ventures, Chairman and CEO of Metavention, Inc., CEO of Cameron Health (Boston Scientific), and Chief Commercial Officer of Visiogen (Abbott). Prior to joining Visiogen, he spent sixteen years at Medtronic in ...